Disease control in patients treated with naxitamab for refractory/relapsed high-risk neuroblastoma

被引：0
|
作者：
Mora, Jaume
Chan, Godfrey C.
Morgenstern, Daniel A.
Amoroso, Loredana
Nysom, Karsten
Faber, Joerg
Wingerter, Arthur
Bear, Melissa
Rubio-San-Simon, Alba
Tornoe, Karen
Koep, Sharif
During, Maria
Kushner, Brian H.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 17期
关键词：
D O I：
10.1158/1538-7445.PEDIATRIC24-B055
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B055
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Dinutuxumab Beta Plus Conventional Chemotherapy for Relapsed/Refractory High-Risk Neuroblastoma: A Single Centre Experience
    Olgun, N.
    Cecen, R. E.
    Ince, D.
    Onal, A.
    Baysal, B.
    Akyol, S.
    Ozdogan, O.
    Guleryuz, H.
    Aktas, S.
    Ozer, E.
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S215 - S215
  • [42] Renal toxicity in paediatric patients with high-risk neuroblastoma treated with radiotherapy
    Gomis Selles, E.
    Burgueno Caballero, A. M.
    Munoz Munoz, O.
    Delgado Leon, B. D.
    Cabrera Roldan, P.
    RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S1220 - S1222
  • [43] Naxitamab and GM-CSF for consolidation of high-risk neuroblastoma (HR-NB) patients in complete remission.
    Mora, Jaume
    Castaneda, Alicia
    Perez-Jaume, Sara
    Gorostegui, Maite
    Santa-Maria, Vicente
    Pablo Munoz, Juan
    Varo, Amalia
    Mane, Salvador
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] Temozolomide as a Single Agent or in Combination for Patients with High Risk Refractory or Relapsed Neuroblastoma: Excellent Tolerance and Sustained Disease Responses
    Metayer, L.
    Annereau, M.
    Abbas, R.
    Hinterlang, M.
    Schleiermacher, G.
    Defachelles, A. S.
    Pasqualini, C.
    Berlanga, P.
    Vassal, G.
    Valteau-Couanet, D.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S33 - S34
  • [45] Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2
    Siebert, Nikolai
    Eger, Christin
    Seidel, Diana
    Juettner, Madlen
    Zumpe, Maxi
    Wegner, Danilo
    Kietz, Silke
    Ehlert, Karoline
    Veal, Gareth J.
    Siegmund, Werner
    Weiss, Michael
    Loibner, Hans
    Ladenstein, Ruth
    Lode, Holger N.
    MABS, 2016, 8 (03) : 604 - 616
  • [46] Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience
    Olgun, Nur
    Cecen, Emre
    Ince, Dilek
    Kizmazoglu, Deniz
    Baysal, Birsen
    Onal, Ayse
    Ozdogan, Ozhan
    Guleryuz, Handan
    Cetingoz, Riza
    Demiral, Ayse
    Olguner, Mustafa
    Celik, Ahmet
    Kamer, Serra
    Ozer, Erdener
    Altun, Zekiye
    Aktas, Safiye
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [47] DINUTUXIMAB BETA-BASED CHEMO-IMMUNOTHERAPY FOR RELAPSED/REFRACTORY HIGH-RISK NEUROBLASTOMA: PRELIMINARY RESULTS
    Olgun, Nur
    Cecen, Emre
    Ince, Dilek
    Kizmazoglu, Deniz
    Baysal, Birsen
    Onal, Ayse
    Ozdogan, Ozhan
    Guleryuz, Handan
    Cetingoz, Riza
    Demiral, Ayse
    Olguner, Mustafa
    Celik, Ahmet
    Kamer, Serra
    Ozer, Erdener
    Altun, Zekiye
    Aktas, Safiye
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S225 - S225
  • [48] THE IMPACT OF POST-INDUCTION TREATMENT ON RESPONSE AND OUTCOMES OF PATIENTS WITH HIGH-RISK NEUROBLASTOMA WITH REFRACTORY DISEASE.
    Siddiqui, A.
    Desai, A.
    Cohn, S.
    Gao, G.
    Oppong, A.
    Yuan, C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S52 - S52
  • [49] Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission
    Mora, Jaume
    Castaneda, Alicia
    Gorostegui, Maite
    Santa-Maria, Vicente
    Garraus, Moira
    Munoz, Juan Pablo
    Varo, Amalia
    Perez-Jaume, Sara
    Mane, Salvador
    PEDIATRIC BLOOD & CANCER, 2021, 68 (10)
  • [50] Survival outcomes in patients with high-risk neuroblastoma (HRNB) in remission after relapsed or refractory treatment receiving eflornithine (DFMO) maintenance.
    Sholler, Giselle Linda Saulnier
    Ferguson, William
    Bergendahl, Genevieve
    Clinch, Thomas
    Kraveka, Jacqueline M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345